The US FDA has recently approved a new genetic test for breast cancer: the SPOT-Light HER2 CISH kit.
This novel genetic test – a product of Invitrogen Corporation – determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab).
The SPOT-Light HER2 CISH kit is a test that measures the number of copies of the HER2 gene in tumor tissue. This gene regulates the growth of cancer cells.
A healthy breast cell has two copies of the HER2 gene, which sends a signal to cells, telling them when to grow, divide and make repairs.
Patients with breast cancer …read more